FDA Puts Access to Abortion over Women’s Health
| FOR IMMEDIATE RELEASE March 30, 2016 |
CONTACT: Ryan Hughes Shirley & Banister Public Affairs 703-739-5920/800-536-5920 rhughes@sbpublicaffairs.com |
Adverse Events Reports Related to Chemical Abortion Drug Must Be Released |
|
| Washington, D.C. – The Food and Drug Administration has revised its guidelines for the abortion-inducing drug Mifeprex — widely known as RU-486 — expanding its use to 70 days of gestation, while recommending lower doses. The revisions are expected to affect several states that have passed laws restricting medication abortion.
“Today the Food and Drug Administration put access to abortion over and above women’s health by extending the use of chemical abortion to two months,” said Jeanne Mancini, President of the March for Life Education & Defense Fund. “RU-486 (chemical abortion) is harder on women physically and involves less medical oversight than surgical abortion. The March for Life calls on the FDA to release the latest adverse events reports related to RU-486, showing the number of complications and deaths related to this drug that was approved in a rushed, politicized fashion back in 2000.” The March for Life in Washington, D.C., began as a small demonstration on January 22, 1974, the first anniversary of the now-infamous Supreme Court decisions in Roe v. Wade and Doe v. Bolton and rapidly grew to be the largest pro-life event in the world. The peaceful demonstration that has followed on this somber anniversary every year since is a witness to the truth concerning the greatest human rights violation of our time, abortion. |
|
| Jeanne Mancini, President of the March for Life Education & Defense Fund is available for commentary. For more information, please contact Ryan Hughes at RHughes@SBPublicAffairs.com or (703) 739-5920.
### |
|
